On June 29, Duality Biotherapeutics-B rose 5.65% in regular trading, trading at HK$173.1/share, with turnover of HK$31.49 million.

On the news front, the company disclosed on June 29 that it repurchased 73,800 shares on June 26 at prices ranging from HK$161.20 to HK$164.40 per share, spending approximately HK$11.99 million. The buyback came after the stock fell 5.18% on June 26 amid broad sector pressure, indicating management actively supporting the share price at lower levels. Additionally, shareholders approved a new buyback authorization at the annual general meeting on June 26, permitting repurchases of up to 9.058 million shares.

At the industry level, the biotech sector saw a broad rebound, with TransThera-B up 20.0%, Remegen up 6.46%, Akeso up 4.5%, Innovent Bio up 2.59%, and BeiGene up 1.75%, creating notable sector-wide momentum.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)